KR950700056A - 분무-냉각된 나부메톤(Spray-chilled nabumetone) - Google Patents
분무-냉각된 나부메톤(Spray-chilled nabumetone)Info
- Publication number
- KR950700056A KR950700056A KR1019940702615A KR19940702615A KR950700056A KR 950700056 A KR950700056 A KR 950700056A KR 1019940702615 A KR1019940702615 A KR 1019940702615A KR 19940702615 A KR19940702615 A KR 19940702615A KR 950700056 A KR950700056 A KR 950700056A
- Authority
- KR
- South Korea
- Prior art keywords
- spray
- cooled
- nabumethone
- nabumetone
- dosage form
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
- C07C49/255—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coating By Spraying Or Casting (AREA)
- Medicines Containing Plant Substances (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Catching Or Destruction (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Road Signs Or Road Markings (AREA)
- Sampling And Sample Adjustment (AREA)
- Freezing, Cooling And Drying Of Foods (AREA)
Abstract
분무-냉각되고 종전의 가능했던 부피보다 작은 부피를 갖는 단위 복용 형태로 배향된 나부메톤
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (14)
- 분무-냉각된 나부메톤.
- 성입 밀도 범위 0.40-0.6g5cm-3를 갖는 분무-냉각된 나부메톤.
- 탭 밀도 범위 0.50-0.65gcm-3를 갖는 분무-냉각된 나부메톤.
- 제약학적으로 허용가능한 부형제와 혼합된 제1-3항중 임의의 한 항에 따른 분무 냉각된 나부메톤을 함유한 제약학적 조성물.
- 제1-4항중 임의의 한 항에 따른 분무-냉각된 나부메톤의 단위 복용 형태.
- 제5항에 있어서, 종래의 보형제와 혼합된 분무-냉각된 나부메톤 500mg을 함유한, 0.480㎤ 미만의 부피를 갖는 연하 정제인 단위 복용 형태.
- 제5항에 있어서, 보형제와 혼합된 분무-냉각된 나부메톤 1000mg을 함유한, 0.960㎤ 미만의 부피를 갖는 연하 정제인 단위 복용 형태.
- 제5-7항중 임의 한 항에 있어서, 보형제로서 충진제를 갖지 않거나 실질적으로 갖지 않는 단위 복용 형태.
- 분무-냉각된 나부메톤 대 보형제의 백분율(중량/중량)이 82% 이상인 제6-8항중 임의의 한 항에 따른 연하 정제.
- 제9항에 있어서, 분무-냉각된 나부메톤 대 보형제의 백분율이 90%이상인 연하 정제.
- 고체 나부메톤을 용융시키고, 그를 분무-급냉기를 갖는 급냉기-실내로 분무시키고, 결과 얻어진 생성물을 수집하는 것으로 구성된 분무-냉각된 나부메톤 제조 방법.
- 제1-11항중 임의의 한 항에 따른 유효량의 분무-냉각된 나부메톤을 그를 필요로 하는 환자에게 투여하는 것으로 구성되는 염증, 염좌, 좌상, 암통증, 열병, 오에스테오포로시스 및 안면근 통증 증후군의 치료 방법.
- 염증, 염좌, 좌상, 암통증, 열병, 오에스테오포로시스 및 안면근 통증 증후군의 치료를 위한 약제를 제조하는데 제1-11항중 임의의 한 항에 따른 분무-냉각된 나부메톤의 사용.
- 실시예 2 및 3을 참고하여 본원에 실질적으로 서술된 바와 같은 분무-냉각된 나부메톤을 함유한 단위 복용 형태.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929201857A GB9201857D0 (en) | 1992-01-29 | 1992-01-29 | Novel compound |
GB9201857.1 | 1992-01-29 | ||
PCT/GB1993/000145 WO1993014747A1 (en) | 1992-01-29 | 1993-01-22 | Spray-chilled nabumetone |
Publications (1)
Publication Number | Publication Date |
---|---|
KR950700056A true KR950700056A (ko) | 1995-01-16 |
Family
ID=10709436
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019940702615A KR950700056A (ko) | 1992-01-29 | 1993-01-22 | 분무-냉각된 나부메톤(Spray-chilled nabumetone) |
Country Status (24)
Country | Link |
---|---|
US (1) | US5539000A (ko) |
EP (1) | EP0624087B1 (ko) |
JP (1) | JPH07503245A (ko) |
KR (1) | KR950700056A (ko) |
CN (1) | CN1079954A (ko) |
AT (1) | ATE150298T1 (ko) |
AU (1) | AU3362693A (ko) |
BG (1) | BG98933A (ko) |
BR (1) | BR9305674A (ko) |
CA (1) | CA2129027A1 (ko) |
CZ (1) | CZ182894A3 (ko) |
DE (1) | DE69309037T2 (ko) |
DK (1) | DK0624087T3 (ko) |
ES (1) | ES2099419T3 (ko) |
FI (1) | FI943550A (ko) |
GB (1) | GB9201857D0 (ko) |
GR (1) | GR3023142T3 (ko) |
HU (1) | HUT67462A (ko) |
IL (1) | IL104526A0 (ko) |
MX (1) | MX9300430A (ko) |
NO (1) | NO942813D0 (ko) |
SK (1) | SK91694A3 (ko) |
WO (1) | WO1993014747A1 (ko) |
ZA (1) | ZA93577B (ko) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030236236A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
GB9920148D0 (en) * | 1999-08-25 | 1999-10-27 | Smithkline Beecham Plc | Novel composition |
US6436990B1 (en) | 1999-10-27 | 2002-08-20 | Nobex Corporation | 6-methoxy-2-naphthylacetic acid prodrugs |
US6552078B2 (en) | 1999-10-27 | 2003-04-22 | Nobex Corp | 6-methoxy-2-naphthylacetic acid prodrugs |
TWI262791B (en) | 1999-10-27 | 2006-10-01 | Nobex Corp | 6-methoxy-2-naphthylacetic acid prodrugs |
US20020132010A1 (en) * | 2000-12-22 | 2002-09-19 | Yihong Qui | Divalproex sodium dosage forms and a process for their production |
US20040161474A1 (en) * | 2002-05-24 | 2004-08-19 | Moerck Rudi E. | Rare earth metal compounds methods of making, and methods of using the same |
US20060083791A1 (en) * | 2002-05-24 | 2006-04-20 | Moerck Rudi E | Rare earth metal compounds methods of making, and methods of using the same |
US20040115287A1 (en) * | 2002-12-17 | 2004-06-17 | Lipocine, Inc. | Hydrophobic active agent compositions and methods |
BRPI0416534A (pt) * | 2003-12-04 | 2007-01-09 | Pfizer Prod Inc | composições multiparticuladas com estabilidade melhorada |
US6984403B2 (en) * | 2003-12-04 | 2006-01-10 | Pfizer Inc. | Azithromycin dosage forms with reduced side effects |
PT1691787E (pt) * | 2003-12-04 | 2008-09-02 | Pfizer Prod Inc | Método de formação de multipartículas farmacêuticas |
BRPI0417348A (pt) * | 2003-12-04 | 2007-03-13 | Pfizer Prod Inc | processo de gelatinização por spray com utilização de uma extrusora para preparação de composições de droga cristalina multiparticulada contendo preferencialmente um poloxámero e um glicerìdeo |
WO2005053652A1 (en) | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride |
WO2005053639A2 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Controlled release multiparticulates formed with dissolution enhancers |
WO2005053653A1 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride |
BRPI0417338A (pt) * | 2003-12-04 | 2007-04-17 | Pfizer Prod Inc | formas de dosagem de azitromicina multiparticulada por processos a base de lìquido |
CA2583548A1 (en) * | 2004-10-15 | 2006-04-27 | Altairnano, Inc. | Phosphate binder with reduced pill burden |
US20080058250A1 (en) * | 2005-08-17 | 2008-03-06 | Allison Wren | Treatment of chronic renal failure and other conditions in domestic animals: compositions and methods |
US8217083B2 (en) * | 2007-06-08 | 2012-07-10 | Aptalis Pharma Canada Inc. | Mesalamine suppository |
US8436051B2 (en) * | 2007-06-08 | 2013-05-07 | Aptalis Pharma Canada Inc. | Mesalamine suppository |
US7541384B2 (en) * | 2007-06-08 | 2009-06-02 | Axcan Pharma Inc. | Mesalamine suppository |
US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
US8961917B2 (en) | 2010-05-12 | 2015-02-24 | Spectrum Pharmaceuticals, Inc. | Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use |
US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
US9498485B2 (en) | 2014-08-28 | 2016-11-22 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
US20170246187A1 (en) | 2014-08-28 | 2017-08-31 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
EP3544614A4 (en) | 2016-11-28 | 2020-08-05 | Lipocine Inc. | ORAL TESTOSTERONE UNDECANOATE THERAPY |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1474377A (en) | 1973-09-11 | 1977-05-25 | Beecham Group Ltd | Naphthalene derivatives |
US4420639C1 (en) * | 1973-09-11 | 2001-08-21 | Beecham Group Ltd | Aromatic compounds |
US4086346A (en) | 1974-04-06 | 1978-04-25 | Bayer Aktiengesellschaft | Preparation of melt-sprayed spherical phenacetin granules |
DE3833446A1 (de) * | 1988-10-01 | 1990-04-05 | Hoechst Ag | Verfahren zur herstellung von arzneimittelwirkstoff-partikeln mit verbesserten fliess-, lager- und formulierungseigenschaften sowie arzneimittel, die diese arzneimittelwirkstoff-partikeln enthalten |
-
1992
- 1992-01-29 GB GB929201857A patent/GB9201857D0/en active Pending
-
1993
- 1993-01-22 BR BR9305674-5A patent/BR9305674A/pt unknown
- 1993-01-22 US US08/030,331 patent/US5539000A/en not_active Expired - Fee Related
- 1993-01-22 KR KR1019940702615A patent/KR950700056A/ko not_active Application Discontinuation
- 1993-01-22 DE DE69309037T patent/DE69309037T2/de not_active Expired - Fee Related
- 1993-01-22 SK SK916-94A patent/SK91694A3/sk unknown
- 1993-01-22 WO PCT/GB1993/000145 patent/WO1993014747A1/en active IP Right Grant
- 1993-01-22 CZ CZ941828A patent/CZ182894A3/cs unknown
- 1993-01-22 AT AT93902444T patent/ATE150298T1/de active
- 1993-01-22 EP EP93902444A patent/EP0624087B1/en not_active Expired - Lifetime
- 1993-01-22 AU AU33626/93A patent/AU3362693A/en not_active Abandoned
- 1993-01-22 DK DK93902444.4T patent/DK0624087T3/da active
- 1993-01-22 JP JP5513026A patent/JPH07503245A/ja active Pending
- 1993-01-22 ES ES93902444T patent/ES2099419T3/es not_active Expired - Lifetime
- 1993-01-22 CA CA002129027A patent/CA2129027A1/en not_active Abandoned
- 1993-01-22 HU HU9402221A patent/HUT67462A/hu unknown
- 1993-01-27 IL IL104526A patent/IL104526A0/xx unknown
- 1993-01-27 ZA ZA93577A patent/ZA93577B/xx unknown
- 1993-01-27 MX MX9300430A patent/MX9300430A/es unknown
- 1993-01-28 CN CN93100940A patent/CN1079954A/zh active Pending
-
1994
- 1994-07-28 BG BG98933A patent/BG98933A/xx unknown
- 1994-07-28 FI FI943550A patent/FI943550A/fi not_active Application Discontinuation
- 1994-07-28 NO NO942813A patent/NO942813D0/no unknown
-
1997
- 1997-04-15 GR GR970400804T patent/GR3023142T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
DE69309037D1 (de) | 1997-04-24 |
NO942813L (no) | 1994-07-28 |
BG98933A (en) | 1995-07-28 |
GB9201857D0 (en) | 1992-03-18 |
EP0624087A1 (en) | 1994-11-17 |
WO1993014747A1 (en) | 1993-08-05 |
EP0624087B1 (en) | 1997-03-19 |
AU3362693A (en) | 1993-09-01 |
IL104526A0 (en) | 1993-05-13 |
ATE150298T1 (de) | 1997-04-15 |
JPH07503245A (ja) | 1995-04-06 |
FI943550A0 (fi) | 1994-07-28 |
DE69309037T2 (de) | 1997-07-24 |
CA2129027A1 (en) | 1993-08-05 |
CN1079954A (zh) | 1993-12-29 |
GR3023142T3 (en) | 1997-07-30 |
MX9300430A (es) | 1994-08-31 |
NO942813D0 (no) | 1994-07-28 |
HU9402221D0 (en) | 1994-09-28 |
SK91694A3 (en) | 1995-03-08 |
ES2099419T3 (es) | 1997-05-16 |
FI943550A (fi) | 1994-07-28 |
BR9305674A (pt) | 2005-01-11 |
DK0624087T3 (da) | 1997-09-01 |
CZ182894A3 (en) | 1995-02-15 |
US5539000A (en) | 1996-07-23 |
ZA93577B (en) | 1994-01-13 |
HUT67462A (en) | 1995-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR950700056A (ko) | 분무-냉각된 나부메톤(Spray-chilled nabumetone) | |
GEP20043216B (en) | Orally Administered Controlled Drug Delivery System | |
MXPA02012666A (es) | Formulaciones farmaceuticas topicas y metodos de tratamiento. | |
RU98111594A (ru) | Фармацевтические композиции, включающие флурбипрофен | |
NO975334D0 (no) | Anvendelse av flavanolignaner for fremstilling av medikamenter med antiproliferativ aktivitet i uterus, ovarium og bryst | |
BR0108379A (pt) | Composições de liberação controlada contendo agonista e antagonista opióide, método para a preparação de uma formulação em dosagem de analgésico opióide de liberação controlada com potência analgésica aumentada e sistema de administração através da derme para um analgésico opióide | |
WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
AU1877992A (en) | Linsidomin for treating erectile dysfunctions | |
KR950703951A (ko) | 광학적으로 순수한 r-케토로락을 포함하는 조성물과 무통과 해열치료에 이를 사용하는 방법(antipyretic and analgesic methods and compositions containing optically pure r-ketorolac) | |
KR930007441A (ko) | 의약품 | |
WO2005055921A3 (en) | Compositions for treatment of ear disorders and methods of use thereof | |
NO20030897D0 (no) | Fremgangsmåte for fremstilling av farmasöytiske sammensetninger for anvendelse med blöte gelatin formuleringer | |
ES2125324T3 (es) | Film para suministro local de un farmaco para un tratamiento periodontal. | |
KR960700063A (ko) | 사람 종양 세포내에서의 테모졸로마이드의 강화방법(Potentiation of temozolomide in human tumour cells) | |
JP2001510795A5 (ko) | ||
RU95101385A (ru) | Продукты, содержащие g-csf и tnf связующие протеина | |
EP1201246A3 (en) | Use of Thrombopoietin as a medicament for the therapy and prevention of thrombocytopenia | |
HUP9901890A2 (hu) | Gyógyszer és eljárás szervezet gyógyszeres kezelésére | |
AR035946A1 (es) | Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos | |
MY124465A (en) | Reduction of infarct volume using citicoline | |
WO1991002529A2 (en) | Product and method for killing abnormal vertebrate cells | |
IL112288A (en) | Use of riluzole in the manufacture of a medicament for the treatment of mitochondrial diseases | |
FR2500303B1 (ko) | ||
NO974486L (no) | Lavdoserte "Ridogrel"-formuleringer samt anvendelse derav ved behandling av tarmbetennelse | |
KR940013503A (ko) | 동맥경화증의 예방 또는 치료용 약제학적 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |